Biologics capacity utilization timing uncertain
The newly acquired biologics facility requires time to ramp up client engagements and reach meaningful utilization; revenue contribution may be limited in initial quarters post-commissioning.
SYNGENE / Q2-FY25 / risks
Keep the risk register visible.
Syngene International · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Pilot project conversion risk
Discovery services recovery is driven by pilot projects with multiple partners being evaluated; conversion to long-term contracts typically takes 12-18 months and success is not guaranteed.
Increasing CDMO competition in India
Entry of generics companies and private equity-backed players into Indian CDMO space could intensify pricing pressure and talent competition, though management expressed confidence in Syngene's established capabilities.
CFO transition execution risk
Sibaji Biswas noted to be departing after five years; incoming CFO Deepak Jain has only been with the company one month. Financial stewardship continuity during this transition period presents execution risk.